Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

$40.30M

Industries

Biotechnology,Health Care,Health Diagnostics,Medical

Founded date

Jan 1, 2005

Number Of Employee

101 - 250

Operating Status

Active

Stock Symbol

nasdaq:BDSX

Legal Name

Biodesix, Inc.

Biodesix is a data-driven diagnostic solutions company that provides lung cancer diagnostic testing and biopharma services. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring, and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops, and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’s first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’s CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.

Biodesix has acquired 2 organizations. Their most recent acquisition was Integrated Diagnostics on Jul 9, 2018. They acquired Integrated Diagnostics for 0.

Date Company Name	Industry	Acquisition Type	Price
Jul 9, 2018 Integrated Diagnostics	Biotechnology	acquisition	—	Detail
Jun 28, 2019 Oncimmune	Biotechnology	acquisition	—	Detail